Form 4: Quest Diagnostics Executive Acquires Shares Through Dividend Reinvestment and Restricted Share Units

Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics, reports acquiring shares through a dividend reinvestment plan and a restricted share unit award.

Summary

• Mark E. Delaney, a Senior Vice President and Chief Commercial Officer at Quest Diagnostics Inc. (DGX), filed a Form 4 with the SEC.
• The filing reports a transaction on October 21, 2024, where Delaney acquired 4 shares of common stock through a dividend reinvestment plan at a price of $149.388 per share.
• Delaney also acquired 5,023 restricted share units.
• Following the reported transactions, Delaney beneficially owns 5,023 shares.
• The reporting person has chosen to report such transaction early on this Form 4.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects routine transactions by an executive, with no clear positive or negative implications for the company's overall outlook.

Positives

• The acquisition of shares through a dividend reinvestment plan demonstrates Delaney's continued investment in the company.
• The award of restricted share units aligns Delaney's interests with the long-term performance of Quest Diagnostics.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. They are closely watched by investors for signals about management's confidence in the company's prospects.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment, reflecting insider confidence.

Key Dates